Sight Sciences, Inc. (NASDAQ:SGHT) Receives Average Rating of “Hold” from Brokerages

Shares of Sight Sciences, Inc. (NASDAQ:SGHT) have earned an average rating of “Hold” from the seven brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $4.70.

A number of analysts have recently issued reports on the company. Piper Sandler reiterated a “neutral” rating and set a $6.00 target price (up previously from $5.00) on shares of Sight Sciences in a report on Friday. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a report on Friday.

Insider Transactions at Sight Sciences

In related news, CFO Alison Bauerlein sold 10,123 shares of the business’s stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total value of $51,424.84. Following the sale, the chief financial officer now directly owns 426,248 shares in the company, valued at approximately $2,165,339.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Alison Bauerlein sold 10,123 shares of the business’s stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total transaction of $51,424.84. Following the sale, the chief financial officer now owns 426,248 shares in the company, valued at $2,165,339.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Paul Badawi sold 12,571 shares of the company’s stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total transaction of $63,860.68. Following the completion of the transaction, the chief executive officer now owns 5,750,729 shares in the company, valued at approximately $29,213,703.32. The disclosure for this sale can be found here. In the last three months, insiders sold 34,129 shares of company stock valued at $173,375. Company insiders own 27.10% of the company’s stock.

Institutional Trading of Sight Sciences

Several large investors have recently added to or reduced their stakes in the business. UBS Group AG boosted its holdings in Sight Sciences by 20,282.6% in the 4th quarter. UBS Group AG now owns 2,895,958 shares of the company’s stock valued at $14,943,000 after purchasing an additional 2,881,750 shares during the period. Jackson Square Partners LLC grew its holdings in Sight Sciences by 12.0% during the 4th quarter. Jackson Square Partners LLC now owns 1,629,746 shares of the company’s stock worth $8,409,000 after acquiring an additional 174,737 shares during the last quarter. First Eagle Investment Management LLC grew its holdings in Sight Sciences by 45.6% during the 3rd quarter. First Eagle Investment Management LLC now owns 587,297 shares of the company’s stock worth $1,979,000 after acquiring an additional 183,912 shares during the last quarter. Boston Partners grew its holdings in Sight Sciences by 3.1% during the 3rd quarter. Boston Partners now owns 331,776 shares of the company’s stock worth $1,117,000 after acquiring an additional 9,919 shares during the last quarter. Finally, RTW Investments LP bought a new stake in Sight Sciences during the 4th quarter worth about $850,000. 55.51% of the stock is owned by institutional investors.

Sight Sciences Trading Up 6.2 %

Shares of SGHT stock opened at $5.96 on Friday. The firm has a 50-day moving average price of $5.11 and a 200 day moving average price of $4.19. Sight Sciences has a twelve month low of $1.04 and a twelve month high of $11.00. The company has a market capitalization of $295.32 million, a price-to-earnings ratio of -5.32 and a beta of 2.73. The company has a current ratio of 13.29, a quick ratio of 12.65 and a debt-to-equity ratio of 0.26.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.13. The company had revenue of $18.75 million during the quarter, compared to analysts’ expectations of $18.70 million. Sight Sciences had a negative return on equity of 42.84% and a negative net margin of 67.18%. During the same quarter in the previous year, the business earned ($0.35) EPS. Research analysts forecast that Sight Sciences will post -1.04 earnings per share for the current fiscal year.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.